Please login to the form below

Not currently logged in
Email:
Password:

Nycomed and Merck reach deal for Daxas

Nycomed has reached a deal with Merck regarding the 'co-promotion' of lung disease drug, Daxas, in Canada and certain European countries

Nycomed has announced it has reached an agreement with Merck regarding the 'co-promotion' of investigational lung disease drug, Daxas (roflumilast), in Canada and certain European countries.

The two companies have also signed an exclusive distribution agreement for the commercialisation of Daxas in the UK.

The deal will see Nycomed receive an undisclosed upfront fee from Merck, with milestone payments based on regulatory and commercial achievements also available.

Daxas is a once-daily drug for patients with chronic obstructive pulmonary disease (COPD) – a collective term for a group of lung diseases that make breathing difficult. It is currently awaiting approval from certain national regulatory bodies, though Nycomed recently announced that the treatment had received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of Daxas in the EU.

If approved, Daxas would be the first oral anti-inflammatory treatment available for COPD, offering an alternative to inhaled bronchodilators and inhaled corticosteroids.

Under the terms of the agreement, Merck and Nycomed will co-promote the drug in France, Germany, Italy, Portugal, Spain and Canada once regulatory approval has been granted. Nycomed will manufacture and distribute the product in these countries.

In the UK, Merck will have exclusive commercial rights for the drug, with Nycomed supplying the finished product and retaining a co-promotion option.

"This agreement with Nycomed for a late-stage PDE4 inhibitor [a treatment to target cells and mediators in the body believed to be important in the COPD disease process] candidate represents a strong strategic fit for Merck," said Kevin Ali, senior vice president and general manager Bone, Respiratory, Immunology and Dermatology franchise at Merck.

"This builds upon Merck's leadership in the asthma and allergy marketplace and positions the company to leverage our well-trained sales force to target the rapidly growing unmet medical need of COPD."

26th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics